Validation of small molecule inhibitors of MALT1 protease for the treatment of auto-immune disorders and NF-κB-addicted lymphomas. KU Leuven
Current scientific literature highlights MALT1 protease activity as an important therapeutic target for treating NF-κB-mediated diseases such as autoimmune disorders and lymphoma. In collaboration with CD3 we have developed and patented three classes of MALT1 small molecule inhibitors that affect MALT1 substrate cleavage in cells and that reduce processes regulated by MALT1 protease activity such as IL2 production by and proliferation of ...